Forecast

There is no analyst data available for this company.

News Go to news feed

Scope Fluidics Spolka Akcyjna Bearer reports quarterly loss per share of 4.17 PLN

Scope Fluidics Spolka Akcyjna Bearer reported figures for the quarter ended 30 September 2025. Earnings per share fell to -4.17 PLN from -2.40 PLN a year earlier; revenue remained unchanged at 0.0 million PLN. » More on finanzen.net
Scope Fluidics reports EPS of -3.14 PLN in latest quarter and strong revenue increase

Scope Fluidics reported earnings per share of -3.14 PLN for the most recent quarter, after -2.420 PLN in the year-ago quarter. Revenue rose 1,200 percent to 0.7 million PLN compared with 0.1 million PLN a year earlier. The figures were presented on 19.09.2025 at the quarterly financial conference. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2023, SCOPE FLUIDICS SA ZY-,10 has already paid 18,24€ in dividends. The last payout was in March 2023.

Financials

In the last quarter, SCOPE FLUIDICS SA ZY-,10 had revenue of 6.29k€ and net profit of −3.14m€

(EUR)	Mar 2026	YoY
Revenue	+6.29k	14,54%
Gross profit	−3.14m	3.420,77%
Net profit	−3.14m	19,52%
EBITDA	−3.26m	30,69%

Fundamentals

Metric	Value
Market capitalization	+100.38m€
Number of shares	3.17m
52-week high/low	+42,02€ - +25,14€
Dividends	No
Beta	0
P/E ratio	−8,10
PEG ratio	+0,05
P/B ratio	+2,92
P/S ratio	+4.185,77

Company profile

Scope Fluidics S.A., ein Biotechnologieunternehmen, beschäftigt sich mit der Konzeption und Entwicklung von Projekten, die auf mikrofluidischen Technologien in der medizinischen Diagnostik und im Gesundheitswesen basieren. Es bietet BacterOMIC, einen Antibiotika-Empfindlichkeitstest, an. Das Unternehmen wurde im Jahr 2010 gegründet und hat seinen Sitz in Warschau, Polen.